Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics (PRQR) EBITDA (2021 - 2025)

Historic EBITDA for ProQR Therapeutics (PRQR) over the last 5 years, with Q3 2025 value amounting to $12.9 million.

  • ProQR Therapeutics' EBITDA rose 3836.62% to $12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.7 million, marking a year-over-year increase of 10506.83%. This contributed to the annual value of -$30.0 million for FY2024, which is 551.73% up from last year.
  • As of Q3 2025, ProQR Therapeutics' EBITDA stood at $12.9 million, which was up 3836.62% from $14.6 million recorded in Q2 2025.
  • In the past 5 years, ProQR Therapeutics' EBITDA ranged from a high of $22.9 million in Q3 2022 and a low of -$20.7 million during Q4 2021
  • Over the past 5 years, ProQR Therapeutics' median EBITDA value was $9.7 million (recorded in 2023), while the average stood at $5.6 million.
  • In the last 5 years, ProQR Therapeutics' EBITDA crashed by 16357.15% in 2023 and then soared by 41855.43% in 2025.
  • Quarter analysis of 5 years shows ProQR Therapeutics' EBITDA stood at -$20.7 million in 2021, then surged by 42.23% to -$11.9 million in 2022, then soared by 43.56% to -$6.7 million in 2023, then tumbled by 59.73% to -$10.8 million in 2024, then soared by 219.69% to $12.9 million in 2025.
  • Its EBITDA stands at $12.9 million for Q3 2025, versus $14.6 million for Q2 2025 and $11.0 million for Q1 2025.